Loading…

Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer

Objective: To elucidate the oncogenic role of human telomerase reverse transcriptase (hTERT) in esophageal squamous cancer and unravel the therapeutic role and molecular mechanism of dihydroartemisinin (DHA) by targeting hTERT. Methods: The expression of hTERT in esophageal squamous cancer and the p...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2021-10, Vol.12, p.769787-769787
Main Authors: Li, Qingrong, Ma, Qiang, Xu, Lei, Gao, Chuanli, Yao, Lihua, Wen, Jilin, Yang, Miyuan, Cheng, Jibing, Zhou, Xi, Zou, Jiang, Zhong, Xiaowu, Guo, Xiaolan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3
cites cdi_FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3
container_end_page 769787
container_issue
container_start_page 769787
container_title Frontiers in pharmacology
container_volume 12
creator Li, Qingrong
Ma, Qiang
Xu, Lei
Gao, Chuanli
Yao, Lihua
Wen, Jilin
Yang, Miyuan
Cheng, Jibing
Zhou, Xi
Zou, Jiang
Zhong, Xiaowu
Guo, Xiaolan
description Objective: To elucidate the oncogenic role of human telomerase reverse transcriptase (hTERT) in esophageal squamous cancer and unravel the therapeutic role and molecular mechanism of dihydroartemisinin (DHA) by targeting hTERT. Methods: The expression of hTERT in esophageal squamous cancer and the patients prognosis were analyzed by bioinformatic analysis from TCGA database, and further validated with esophageal squamous cancer tissues in our cohort. The Cell Counting Kit-8 (CCK8) and colony formation assay were used to evaluate the proliferation of esophageal squamous cancer cell lines (Eca109, KYSE150, and TE1) after hTERT overexpression or treated with indicated concentrations of DHA. Transwell migration assay and scratch assay were employed to determine the migration abilities of cancer cells. Fluorescence microscopy and flow cytometry were conducted to measure the intracellular reactive oxygen species (ROS) levels in cancer cells after treated with DHA. Moreover, RT-PCR and Western blot were performed to test the alteration of associated genes on mRNA and protein level in DHA treated esophageal squamous cancer cell lines, respectively. Furthermore, tumor-bearing nude mice were employed to evaluate the anticancer effect of DHA in vivo . Results: We found that hTERT was significantly upregulated in esophageal squamous cancer both from TCGA database and our cohort also. Overexpression of hTERT evidently promoted the proliferation and migration of esophageal squamous cancer cells in vitro . Moreover, DHA could significantly inhibit the proliferation and migration of esophageal cancer cell lines Eca109, KYSE150, and TE1 in vitro , and significantly down-regulate the expression of hTERT on both mRNA and protein level in a time- and dose-dependent manner as well. Further studies showed that DHA could induce intracellular ROS production in esophageal cancer cells and down-regulate SP1 expression, a transcription factor that bound to the promoter region of hTERT gene. Moreover, overexpression of SP1 evidently promoted the proliferation and migration of Eca109 and TE1 cells. Intriguingly, rescue experiments showed that inhibiting ROS by NAC alleviated the downregulation of SP1 and hTERT in cells treated with DHA. Furthermore, overexpression of SP1 or hTERT could attenuate the inhibition effect of DHA on the proliferation and migration of Eca109 cells. In tumor-bearing nude mice model, DHA significantly inhibited the growth of esophageal squamous cancer xenograf
doi_str_mv 10.3389/fphar.2021.769787
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_45df7d6c7a904a82816ea337056e552e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_45df7d6c7a904a82816ea337056e552e</doaj_id><sourcerecordid>2595100897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3</originalsourceid><addsrcrecordid>eNpVkU1rHDEMhofS0oQ0P6A3H3vZrb89vhTKNm0CgUK7PRutR951mBlP7JlA_n292RASYZCRXh4JvU3zmdG1EK39GqYD5DWnnK2NtqY175pzprVY2Zbx96_-Z81lKXe0hrBWaPmxORPSyPrseVOulwFGssU-DZihIPmDD5hr3mYYi89xmo9VKATI9lAlEy5z9GQLeY8zSYH8iIfHLifIMw6xxDGOJKRMrkqqG-4RevL3foEhLYVsYPSYPzUfAvQFL5_zRfPv59V2c726_f3rZvP9duWl5PPKK21YoDtkNAiOFBXsPAoTQlC089Kj9NooDMIrZSkI441SATUDSrnciYvm5sTtEty5KccB8qNLEN1TIeW9q0tH36OTqgum096ApRJa3jKNIIShSqNSHCvr24k1LbsBO4_jnKF_A33bGePB7dODa5W2XNAK-PIMyOl-wTK7eiyPfQ8j1tM4rqxilLbWVCk7SX1OpWQML2MYdUfv3ZP37ui9O3kv_gOmbqSW</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595100897</pqid></control><display><type>article</type><title>Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer</title><source>PubMed Central</source><creator>Li, Qingrong ; Ma, Qiang ; Xu, Lei ; Gao, Chuanli ; Yao, Lihua ; Wen, Jilin ; Yang, Miyuan ; Cheng, Jibing ; Zhou, Xi ; Zou, Jiang ; Zhong, Xiaowu ; Guo, Xiaolan</creator><creatorcontrib>Li, Qingrong ; Ma, Qiang ; Xu, Lei ; Gao, Chuanli ; Yao, Lihua ; Wen, Jilin ; Yang, Miyuan ; Cheng, Jibing ; Zhou, Xi ; Zou, Jiang ; Zhong, Xiaowu ; Guo, Xiaolan</creatorcontrib><description>Objective: To elucidate the oncogenic role of human telomerase reverse transcriptase (hTERT) in esophageal squamous cancer and unravel the therapeutic role and molecular mechanism of dihydroartemisinin (DHA) by targeting hTERT. Methods: The expression of hTERT in esophageal squamous cancer and the patients prognosis were analyzed by bioinformatic analysis from TCGA database, and further validated with esophageal squamous cancer tissues in our cohort. The Cell Counting Kit-8 (CCK8) and colony formation assay were used to evaluate the proliferation of esophageal squamous cancer cell lines (Eca109, KYSE150, and TE1) after hTERT overexpression or treated with indicated concentrations of DHA. Transwell migration assay and scratch assay were employed to determine the migration abilities of cancer cells. Fluorescence microscopy and flow cytometry were conducted to measure the intracellular reactive oxygen species (ROS) levels in cancer cells after treated with DHA. Moreover, RT-PCR and Western blot were performed to test the alteration of associated genes on mRNA and protein level in DHA treated esophageal squamous cancer cell lines, respectively. Furthermore, tumor-bearing nude mice were employed to evaluate the anticancer effect of DHA in vivo . Results: We found that hTERT was significantly upregulated in esophageal squamous cancer both from TCGA database and our cohort also. Overexpression of hTERT evidently promoted the proliferation and migration of esophageal squamous cancer cells in vitro . Moreover, DHA could significantly inhibit the proliferation and migration of esophageal cancer cell lines Eca109, KYSE150, and TE1 in vitro , and significantly down-regulate the expression of hTERT on both mRNA and protein level in a time- and dose-dependent manner as well. Further studies showed that DHA could induce intracellular ROS production in esophageal cancer cells and down-regulate SP1 expression, a transcription factor that bound to the promoter region of hTERT gene. Moreover, overexpression of SP1 evidently promoted the proliferation and migration of Eca109 and TE1 cells. Intriguingly, rescue experiments showed that inhibiting ROS by NAC alleviated the downregulation of SP1 and hTERT in cells treated with DHA. Furthermore, overexpression of SP1 or hTERT could attenuate the inhibition effect of DHA on the proliferation and migration of Eca109 cells. In tumor-bearing nude mice model, DHA significantly inhibited the growth of esophageal squamous cancer xenografts, and downregulated the expression of SP1 and hTERT protein, while no side effects were observed from heart, kidney, liver, and lung tissues by HE stain. Conclusion: hTERT plays an oncogenic role in esophageal squamous cancer and might be a therapeutic target of DHA through regulating ROS/SP1 pathway.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2021.769787</identifier><identifier>PMID: 34744749</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>dihydroartemisinin ; esophageal squamous cancer ; Pharmacology ; reactive oxygen species ; specificity protein 1 ; telomerase reverse transcriptase</subject><ispartof>Frontiers in pharmacology, 2021-10, Vol.12, p.769787-769787</ispartof><rights>Copyright © 2021 Li, Ma, Xu, Gao, Yao, Wen, Yang, Cheng, Zhou, Zou, Zhong and Guo. 2021 Li, Ma, Xu, Gao, Yao, Wen, Yang, Cheng, Zhou, Zou, Zhong and Guo</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3</citedby><cites>FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569230/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569230/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Li, Qingrong</creatorcontrib><creatorcontrib>Ma, Qiang</creatorcontrib><creatorcontrib>Xu, Lei</creatorcontrib><creatorcontrib>Gao, Chuanli</creatorcontrib><creatorcontrib>Yao, Lihua</creatorcontrib><creatorcontrib>Wen, Jilin</creatorcontrib><creatorcontrib>Yang, Miyuan</creatorcontrib><creatorcontrib>Cheng, Jibing</creatorcontrib><creatorcontrib>Zhou, Xi</creatorcontrib><creatorcontrib>Zou, Jiang</creatorcontrib><creatorcontrib>Zhong, Xiaowu</creatorcontrib><creatorcontrib>Guo, Xiaolan</creatorcontrib><title>Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer</title><title>Frontiers in pharmacology</title><description>Objective: To elucidate the oncogenic role of human telomerase reverse transcriptase (hTERT) in esophageal squamous cancer and unravel the therapeutic role and molecular mechanism of dihydroartemisinin (DHA) by targeting hTERT. Methods: The expression of hTERT in esophageal squamous cancer and the patients prognosis were analyzed by bioinformatic analysis from TCGA database, and further validated with esophageal squamous cancer tissues in our cohort. The Cell Counting Kit-8 (CCK8) and colony formation assay were used to evaluate the proliferation of esophageal squamous cancer cell lines (Eca109, KYSE150, and TE1) after hTERT overexpression or treated with indicated concentrations of DHA. Transwell migration assay and scratch assay were employed to determine the migration abilities of cancer cells. Fluorescence microscopy and flow cytometry were conducted to measure the intracellular reactive oxygen species (ROS) levels in cancer cells after treated with DHA. Moreover, RT-PCR and Western blot were performed to test the alteration of associated genes on mRNA and protein level in DHA treated esophageal squamous cancer cell lines, respectively. Furthermore, tumor-bearing nude mice were employed to evaluate the anticancer effect of DHA in vivo . Results: We found that hTERT was significantly upregulated in esophageal squamous cancer both from TCGA database and our cohort also. Overexpression of hTERT evidently promoted the proliferation and migration of esophageal squamous cancer cells in vitro . Moreover, DHA could significantly inhibit the proliferation and migration of esophageal cancer cell lines Eca109, KYSE150, and TE1 in vitro , and significantly down-regulate the expression of hTERT on both mRNA and protein level in a time- and dose-dependent manner as well. Further studies showed that DHA could induce intracellular ROS production in esophageal cancer cells and down-regulate SP1 expression, a transcription factor that bound to the promoter region of hTERT gene. Moreover, overexpression of SP1 evidently promoted the proliferation and migration of Eca109 and TE1 cells. Intriguingly, rescue experiments showed that inhibiting ROS by NAC alleviated the downregulation of SP1 and hTERT in cells treated with DHA. Furthermore, overexpression of SP1 or hTERT could attenuate the inhibition effect of DHA on the proliferation and migration of Eca109 cells. In tumor-bearing nude mice model, DHA significantly inhibited the growth of esophageal squamous cancer xenografts, and downregulated the expression of SP1 and hTERT protein, while no side effects were observed from heart, kidney, liver, and lung tissues by HE stain. Conclusion: hTERT plays an oncogenic role in esophageal squamous cancer and might be a therapeutic target of DHA through regulating ROS/SP1 pathway.</description><subject>dihydroartemisinin</subject><subject>esophageal squamous cancer</subject><subject>Pharmacology</subject><subject>reactive oxygen species</subject><subject>specificity protein 1</subject><subject>telomerase reverse transcriptase</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1rHDEMhofS0oQ0P6A3H3vZrb89vhTKNm0CgUK7PRutR951mBlP7JlA_n292RASYZCRXh4JvU3zmdG1EK39GqYD5DWnnK2NtqY175pzprVY2Zbx96_-Z81lKXe0hrBWaPmxORPSyPrseVOulwFGssU-DZihIPmDD5hr3mYYi89xmo9VKATI9lAlEy5z9GQLeY8zSYH8iIfHLifIMw6xxDGOJKRMrkqqG-4RevL3foEhLYVsYPSYPzUfAvQFL5_zRfPv59V2c726_f3rZvP9duWl5PPKK21YoDtkNAiOFBXsPAoTQlC089Kj9NooDMIrZSkI441SATUDSrnciYvm5sTtEty5KccB8qNLEN1TIeW9q0tH36OTqgum096ApRJa3jKNIIShSqNSHCvr24k1LbsBO4_jnKF_A33bGePB7dODa5W2XNAK-PIMyOl-wTK7eiyPfQ8j1tM4rqxilLbWVCk7SX1OpWQML2MYdUfv3ZP37ui9O3kv_gOmbqSW</recordid><startdate>20211022</startdate><enddate>20211022</enddate><creator>Li, Qingrong</creator><creator>Ma, Qiang</creator><creator>Xu, Lei</creator><creator>Gao, Chuanli</creator><creator>Yao, Lihua</creator><creator>Wen, Jilin</creator><creator>Yang, Miyuan</creator><creator>Cheng, Jibing</creator><creator>Zhou, Xi</creator><creator>Zou, Jiang</creator><creator>Zhong, Xiaowu</creator><creator>Guo, Xiaolan</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211022</creationdate><title>Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer</title><author>Li, Qingrong ; Ma, Qiang ; Xu, Lei ; Gao, Chuanli ; Yao, Lihua ; Wen, Jilin ; Yang, Miyuan ; Cheng, Jibing ; Zhou, Xi ; Zou, Jiang ; Zhong, Xiaowu ; Guo, Xiaolan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>dihydroartemisinin</topic><topic>esophageal squamous cancer</topic><topic>Pharmacology</topic><topic>reactive oxygen species</topic><topic>specificity protein 1</topic><topic>telomerase reverse transcriptase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Qingrong</creatorcontrib><creatorcontrib>Ma, Qiang</creatorcontrib><creatorcontrib>Xu, Lei</creatorcontrib><creatorcontrib>Gao, Chuanli</creatorcontrib><creatorcontrib>Yao, Lihua</creatorcontrib><creatorcontrib>Wen, Jilin</creatorcontrib><creatorcontrib>Yang, Miyuan</creatorcontrib><creatorcontrib>Cheng, Jibing</creatorcontrib><creatorcontrib>Zhou, Xi</creatorcontrib><creatorcontrib>Zou, Jiang</creatorcontrib><creatorcontrib>Zhong, Xiaowu</creatorcontrib><creatorcontrib>Guo, Xiaolan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Qingrong</au><au>Ma, Qiang</au><au>Xu, Lei</au><au>Gao, Chuanli</au><au>Yao, Lihua</au><au>Wen, Jilin</au><au>Yang, Miyuan</au><au>Cheng, Jibing</au><au>Zhou, Xi</au><au>Zou, Jiang</au><au>Zhong, Xiaowu</au><au>Guo, Xiaolan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer</atitle><jtitle>Frontiers in pharmacology</jtitle><date>2021-10-22</date><risdate>2021</risdate><volume>12</volume><spage>769787</spage><epage>769787</epage><pages>769787-769787</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Objective: To elucidate the oncogenic role of human telomerase reverse transcriptase (hTERT) in esophageal squamous cancer and unravel the therapeutic role and molecular mechanism of dihydroartemisinin (DHA) by targeting hTERT. Methods: The expression of hTERT in esophageal squamous cancer and the patients prognosis were analyzed by bioinformatic analysis from TCGA database, and further validated with esophageal squamous cancer tissues in our cohort. The Cell Counting Kit-8 (CCK8) and colony formation assay were used to evaluate the proliferation of esophageal squamous cancer cell lines (Eca109, KYSE150, and TE1) after hTERT overexpression or treated with indicated concentrations of DHA. Transwell migration assay and scratch assay were employed to determine the migration abilities of cancer cells. Fluorescence microscopy and flow cytometry were conducted to measure the intracellular reactive oxygen species (ROS) levels in cancer cells after treated with DHA. Moreover, RT-PCR and Western blot were performed to test the alteration of associated genes on mRNA and protein level in DHA treated esophageal squamous cancer cell lines, respectively. Furthermore, tumor-bearing nude mice were employed to evaluate the anticancer effect of DHA in vivo . Results: We found that hTERT was significantly upregulated in esophageal squamous cancer both from TCGA database and our cohort also. Overexpression of hTERT evidently promoted the proliferation and migration of esophageal squamous cancer cells in vitro . Moreover, DHA could significantly inhibit the proliferation and migration of esophageal cancer cell lines Eca109, KYSE150, and TE1 in vitro , and significantly down-regulate the expression of hTERT on both mRNA and protein level in a time- and dose-dependent manner as well. Further studies showed that DHA could induce intracellular ROS production in esophageal cancer cells and down-regulate SP1 expression, a transcription factor that bound to the promoter region of hTERT gene. Moreover, overexpression of SP1 evidently promoted the proliferation and migration of Eca109 and TE1 cells. Intriguingly, rescue experiments showed that inhibiting ROS by NAC alleviated the downregulation of SP1 and hTERT in cells treated with DHA. Furthermore, overexpression of SP1 or hTERT could attenuate the inhibition effect of DHA on the proliferation and migration of Eca109 cells. In tumor-bearing nude mice model, DHA significantly inhibited the growth of esophageal squamous cancer xenografts, and downregulated the expression of SP1 and hTERT protein, while no side effects were observed from heart, kidney, liver, and lung tissues by HE stain. Conclusion: hTERT plays an oncogenic role in esophageal squamous cancer and might be a therapeutic target of DHA through regulating ROS/SP1 pathway.</abstract><pub>Frontiers Media S.A</pub><pmid>34744749</pmid><doi>10.3389/fphar.2021.769787</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2021-10, Vol.12, p.769787-769787
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_45df7d6c7a904a82816ea337056e552e
source PubMed Central
subjects dihydroartemisinin
esophageal squamous cancer
Pharmacology
reactive oxygen species
specificity protein 1
telomerase reverse transcriptase
title Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20Telomerase%20Reverse%20Transcriptase%20as%20a%20Therapeutic%20Target%20of%20Dihydroartemisinin%20for%20Esophageal%20Squamous%20Cancer&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Li,%20Qingrong&rft.date=2021-10-22&rft.volume=12&rft.spage=769787&rft.epage=769787&rft.pages=769787-769787&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2021.769787&rft_dat=%3Cproquest_doaj_%3E2595100897%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-c5671f0be10f32e0e5abce37fff50dc4ce4c675ef3c5590a37c755fe61a0024b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2595100897&rft_id=info:pmid/34744749&rfr_iscdi=true